The Alzheimer’s Drugs Market is projected to reach $9.62 billion by 2031, growing at a CAGR of 9.8% from 2024 to 2031. The market growth is driven by the increasing global burden of Alzheimer's disease, rising prevalence of risk factors, surge in research funding, introduction of innovative technologies, increasing number of approvals, and a growing pipeline of clinical trials and products. Additional growth opportunities are expected from expanding research activities in developing countries, heightened awareness programs, public and private initiatives, combination drug therapies, and advanced biomarkers and imaging techniques for diagnosis and management.



Free Download sample report here: https://www.meticulousresearch.com/download-sample-report/cp_id=5947



Key Market Growth Drivers

Increasing Burden of Alzheimer’s Disease

Alzheimer’s disease, the most common type of dementia, causes a progressive decline in memory, organizing, learning, and thinking skills. The prevalence of neurodegenerative disorders like Alzheimer's is increasing due to aging populations, traumatic brain injuries, genetic factors, stress, and other lifestyle risk factors. According to the Alzheimer's Association (U.S.), the prevalence of Alzheimer’s disease among those aged 65 and older is projected to rise from 6.2 million in 2021 to 6.9 million in 2024. This growing prevalence is expected to drive demand for Alzheimer’s drugs.



Increase in Research Funding

With the increasing prevalence of Alzheimer’s disease, there is a rising need for novel therapies. Both public and private entities are significantly funding research to understand the disease better and develop effective treatments.



For instance, Alzheimer’s and dementia research funding at the National Institutes of Health (NIH) increased from USD 2.8 billion in 2021 to USD 3.8 billion in 2023. Key recent funding highlights include:

May 2024: NeuroTherapia received a grant from the Alzheimer's Association to develop its NTRX-07 drug for Alzheimer's treatment.

October 2023: The National Institute on Aging awarded USD 151 million to the University of California San Francisco for a clinical trial combining anti-amyloid and tau therapies.



Emerging Market Trends

Stem Cell Therapy

Stem cell therapy is a promising treatment for Alzheimer’s disease, reducing amyloid β-protein deposition and alleviating memory loss symptoms. The first stem cell therapy for Alzheimer’s was approved in Japan in 2018, leading to increased research and clinical trials in this field.





Telehealth in Alzheimer’s Care

Telehealth offers a cost-effective and convenient alternative to traditional long-term residential care for Alzheimer's patients. It provides services such as consultations, medication management, and follow-up appointments via video conferencing. Telehealth improves patient adherence to treatment regimens, thereby managing symptoms more effectively and driving market growth.



Browse in depth: https://www.meticulousresearch.com/product/alzheimers-drugs-market-5947

Market Opportunities

Combination Therapy

Combination therapy, using two therapeutic agents together, shows promise in treating Alzheimer’s disease. For instance, combining memantine with cholinesterase inhibitors has demonstrated higher efficacy in clinical trials compared to monotherapy. This approach targets multiple pathways involved in Alzheimer’s, offering potential benefits to patients.



Market Segmentation Analysis

By Drug Type

Cholinesterase Inhibitors: Expected to dominate with a 46.9% market share in 2024 due to their effectiveness in treating mild to moderate Alzheimer’s by decreasing acetylcholine breakdown.

NMDA Receptor Antagonists

Glutamate Regulators

Combination Drugs



By Application

Symptom Management: Predicted to account for 87.2% of the market in 2024. Symptom management drugs slow disease progression, reduce healthcare costs, and address symptoms like impaired judgment and memory loss, increasing their demand.



Geographical Analysis

North America

North America is expected to hold the largest market share (43.0%) in 2024, driven by the high prevalence of Alzheimer’s, substantial research funding, the presence of key players, numerous clinical trials, and favorable reimbursement policies. For instance, in February 2024, the Centers for Medicare & Medicaid Services covered Leqembi (Lecanemab), a recently approved Alzheimer’s medication.



Asia-Pacific

Asia-Pacific is anticipated to register the highest growth rate (11.4%) during the forecast period, with significant opportunities in China, India, and South Korea. Factors include a growing pharmaceutical industry, supportive government initiatives, and extensive clinical trials. For example, Bredis Healthcare received USD 1.27 million from the South Korean Ministry of SMEs and Startups in August 2023 for developing diagnostic tests for Alzheimer’s.

Quick buy: https://www.meticulousresearch.com/Checkout/23211142

Leading Companies

Key players in the Alzheimer’s drugs market include Biogen, Novartis AG, F. Hoffmann-La Roche AG, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Eisai Co., Ltd., SUPERNUS PHARMACEUTICALS, INC., H. Lundbeck A/S, AC Immune SA, Zydus Lifesciences Limited, Johnson & Johnson, and Daiichi Sankyo Company. These companies are recognized for their extensive product portfolios, strategic geographical presence, and robust growth strategies from 2020 to 2024.



Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research